AN2 Therapeutics, Inc.【ANTX】

時価総額

$1.4億

PER

臨床段階のバイオ医薬品の新興企業。結核・メラロイドーシス向け小分子抗菌薬エペトラボールの開発を展開。2019年にAnacorへ前払2.0百万ドルで独占ライセンス取得、2023年8月の増資で65.5百万ドルを調達。米国・中国・香港・台湾・マカオ・結核流行国中心の展開。

	2022年 12月31日	2023年 12月31日	2024年 12月31日
Net Loss	-41	-65	-51
Stock-based compensation expense	4	8	8
Noncash Operating Lease Expense	0	0	-
Net accretion of discount on investments	1	3	3
Prepaid expenses and other assets	1	1	-1
Accounts payable	2	1	1
Accrued compensation	1	2	-2
Accrued liabilities	2	4	-2
Operating lease liabilities	-0	-0	-
Other current liabilities	-	1	0
Net cash used in operating activities	-33	-53	-49
Purchases of investments	94	132	47
Maturities of investments	72	89	101
Net cash provided by (used in) investing activities	-22	-43	55
Proceeds from issuance of common stock from the Underwritten Offering net of commissions and offering expenses	-	65	-
Proceeds From Issuance Of Common Stock From At The Market Offering Net Of Commissions And Offering Expenses	-	19	-
Proceeds from Issuance of Common Stock	-	0	0
Proceeds from Stock Options Exercised	-	0	0
Proceeds from Issuance Initial Public Offering	70	-	-
Repurchase of early exercised stock options	0	-	-
Net cash provided by financing activities	70	85	0
Net increase (decrease) in cash and cash equivalents	15	-12	6
Conversion of Stock, Amount Converted	111	-	-
Accretion to redemption value and cumulative dividends on preferred stock	2	-	-